{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T07:08:07Z","timestamp":1722064087503},"reference-count":30,"publisher":"Galenos Yayinevi","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2022.2022.0142","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T14:02:43Z","timestamp":1654264963000},"page":"254-261","source":"Crossref","is-referenced-by-count":1,"title":["Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience"],"prefix":"10.4274","volume":"39","author":[{"given":"Murat","family":"\u00d6zbalak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metban","family":"Mastanzade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"\u00d6zden \u00d6zl\u00fck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tar\u0131k Onur","family":"Tiryaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simge","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezgi P\u0131nar","family":"\u00d6zbalak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu\u011frul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130pek","family":"Y\u00f6nal Hindilerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Y\u0131lmaz","family":"Altay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcl\u00e7in","family":"Ye\u011fen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Nuri","family":"Yenerel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teoman","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meliha","family":"Nal\u00e7ac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burhan","family":"Ferhano\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevgi","family":"Kalayo\u011flu Be\u015f\u0131\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","unstructured":"1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.","journal-title":"N Engl J Med"},{"key":"ref1","unstructured":"2. US Food and Drug Administration. Biosimilars. Available at https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Muller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P. The advent of biosimilars: challenges and risks. Swiss Med Wkly 2014;144:w13980.","DOI":"10.4414\/smw.2014.13980"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4103\/0971-5851.125248","article-title":"Comparison of the efficacy and safety of Rituximab (Mabthera) and its biosimilar (Reditux) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis","volume":"34","author":"Roy","year":"2013","unstructured":"4. Roy PS, John S, Karankal S, Kannan S, Pawaskar P, Gawande J, Bagal B, Khattry N, Sengar M, Menon H, Gujral S, Nair R. Comparison of the efficacy and safety of Rituximab (Mabthera) and its biosimilar (Reditux) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol 2013;34:292-298.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4274\/iksstd.2021.35761","article-title":"R-CHOP chemotherapy with a rituximab biosimilar (Redditux\u00ae) for patients with de novo diffuse large B-cell lymphoma: first preliminary results of a real-life single-center experience from turkey","volume":"13","author":"\u00d6zbalak","year":"2021","unstructured":"5. \u00d6zbalak M, Mastanzade M, \u00d6zl\u00fck \u00d6, Tiryaki TO, P\u0131nar \u00d6zbalak E, Yonal-Hindilerden \u0130, Altay AY, Ye\u011fen G, Yenerel MN, Nal\u00e7ac\u0131 M, Kalayo\u011flu Be\u015f\u0131\u015f\u0131k S. R-CHOP chemotherapy with a rituximab biosimilar (Redditux\u00ae) for patients with de novo diffuse large B-cell lymphoma: first preliminary results of a real-life single-center experience from turkey. \u0130stanbul Kanuni Sultan S\u00fcleyman T\u0131p Dergisi 2021;13:194-198.","journal-title":"\u0130stanbul Kanuni Sultan S\u00fcleyman T\u0131p Dergisi"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"908191","DOI":"10.1155\/2013\/908191","article-title":"Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study","volume":"2013","author":"Ozbalak","year":"2013","unstructured":"6. Ozbalak M, Ar MC, Tuzuner N, Salihoglu A, Eskazan AE, Ongoren Aydin S, Baslar Z, Soysal T, Aydin Y, Barak Dolgun A, Ergonul O, Ferhanoglu B. Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study. ISRN Hematology 2013;2013:908191.","journal-title":"ISRN Hematology"},{"key":"ref6","unstructured":"7. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","unstructured":"8. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","unstructured":"9. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","article-title":"Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study","volume":"9","author":"Pfreundschuh","year":"2008","unstructured":"10. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435-444.","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","unstructured":"11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.","journal-title":"Am J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"BD","year":"2014","unstructured":"12. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068.","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andre M, Johnson PW, Pfreundschuh M, Ladetto M, Committee EG. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):116-125.","DOI":"10.1093\/annonc\/mdv304"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","unstructured":"14. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2016;34:3150-3156.","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1600-0609.2010.01566.x","article-title":"Biosimilar agents in oncology\/haematology: from approval to practice","volume":"86","author":"Niederwieser","year":"2011","unstructured":"15. Niederwieser D, Schmitz S. Biosimilar agents in oncology\/haematology: from approval to practice. Eur J Haematol 2011;86:277-288.","journal-title":"Eur J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12288-019-01167-w","article-title":"Comparison of the efficacy of innovator rituximab and its biosimilars in diffuse large B cell lymphoma patients: a retrospective analysis","volume":"36","author":"Bankar","year":"2020","unstructured":"16. Bankar A, Korula A, Abraham A, Viswabandya A, George B, Srivastava A, Mathews V. Comparison of the efficacy of innovator rituximab and its biosimilars in diffuse large B cell lymphoma patients: a retrospective analysis. Indian J Hematol Blood Transfus 2020;36:71-77.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jgo.19.00248","article-title":"Randomized, double-blind, pharmacokinetic equivalence trial comparing DRL-rituximab with MabThera in patients with diffuse large B-cell lymphoma","volume":"5","author":"Viswabandya","year":"2019","unstructured":"17. Viswabandya A, Shah S, Mukhopadhyay A, Nagarkar RV, Batra SS, Lopez-Lazaro L, Kankanwadi S, Srivastava A. Randomized, double-blind, pharmacokinetic equivalence trial comparing DRL-rituximab with MabThera in patients with diffuse large B-cell lymphoma. J Glob Oncol 2019;5:1-13.","journal-title":"J Glob Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/bloodadvances.2021004295","article-title":"Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study","volume":"5","author":"Brink","year":"2021","unstructured":"18. Brink M, Kahle XU, Vermaat JSP, Zijlstra JM, Chamuleau M, Kersten MJ, Durmaz M, Plattel WJ, Lugtenburg PJ, Stevens W, Mous R, de Vries EGE, van der Poel MWM, Panday PVN, Huls G, van Meerten T, Nijland M. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Adv 2021;5:2958-2964.","journal-title":"Blood Adv"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1080\/10428194.2019.1633632","article-title":"Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study","volume":"60","author":"Candelaria","year":"2019","unstructured":"19. Candelaria M, Gonzalez DE, Delamain MT, Bar DO, Beniwal SK, Dasappa L, Flores DH, Querol J, Guan TS, Lipatov ON, Volodicheva EM, Patel M, Safaee Nodehi SR, Fogliatto L, Paravisini A, Perez Diaz L; RTXM83 Study. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Leuk Lymphoma 2019;60:3375-3385.","journal-title":"Leuk Lymphoma"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-020-00871-9","article-title":"A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma","volume":"13","author":"Shi","year":"2020","unstructured":"20. Shi Y, Song Y, Qin Y, Zhang Q, Han X, Hong X, Wang D, Li W, Zhang Y, Feng J, Yang J, Zhang H, Jin C, Yang Y, Hu J, Wang Z, Jin Z, Su H, Wang H, Yang H, Fu W, Zhang M, Zhang X, Chen Y, Ke X, Liu L, Yu D, Chen G, Wang X, Jin J, Sun T, Du X, Cheng Y, Yi P, Zhao X, Ma C, Cheng J, Chai K, Luk A, Liu E, Zhang X. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. J Hematol Oncol 2020;13:38.","journal-title":"J Hematol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1080\/10428194.2020.1742906","article-title":"The clinical outcomes of rituximab biosimilar CT-P10 (Truxima\u00ae) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience","volume":"61","author":"Lee","year":"2020","unstructured":"21. Lee K, Ha JY, Jung AR, Lee YS, Lee SW, Ryu JS, Chae EJ, Kim KW, Huh J, Park CS, Yoon DH, Suh C. The clinical outcomes of rituximab biosimilar CT-P10 (Truxima\u00ae) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. Leuk Lymphoma 2020;61:1575-1583.","journal-title":"Leuk Lymphoma"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s12325-020-01603-8","article-title":"Efficacy and safety of the biosimilar IBI301 plus standard CHOP (I-CHOP) in comparison with rituximab plus CHOP (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a randomized, double-blind, parallel-group, phase 3 trial","volume":"38","author":"Song","year":"2021","unstructured":"22. Song Y, Zhou H, Zhang H, Liu W, Shuang Y, Zhou K, Lv F, Xu H, Zhou J, Li W, Wang H, Zhang H, Huang H, Zhang Q, Xu W, Ge Z, Xiang Y, Wang S, Gao D, Yang S, Lin J, Wang L, Zou L, Zheng M, Liu J, Shao Z, Pang Y, Xia R, Chen Z, Hou M, Yao H, Feng R, Cai Z, Zhang M, Ran W, Liu L, Zeng S, Yang W, Liu P, Liang A, Zuo X, Zou Q, Ma J, Sang W, Guo Y, Zhang W, Cao Y, Li Y, Feng J, Du X, Zhang X, Zhao H, Zhou H, Yu J, Sun X, Zhu J, Qiu L. Efficacy and safety of the biosimilar IBI301 plus standard CHOP (I-CHOP) in comparison with rituximab plus CHOP (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a randomized, double-blind, parallel-group, phase 3 trial. Adv Ther 2021;38:1889-1903.","journal-title":"Adv Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-016-3083-x","article-title":"Population pharmacokinetics of Reditux, a biosimilar Rituximab, in diffuse large B-cell lymphoma","volume":"78","author":"Gota","year":"2016","unstructured":"23. Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, Sengar M, Nair R, Menon H. Population pharmacokinetics of Reditux, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 2016;78:353-359.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00280-016-3176-6","article-title":"on their article \"the pharmacokinetics of Reditux, a biosimilar of rituximab\"","volume":"78","author":"Tout","year":"2016","unstructured":"24. Tout M, Passot C, Cartron G, Paintaud G, Ternant D. Gota et al. on their article \"the pharmacokinetics of Reditux, a biosimilar of rituximab\". Cancer Chemother Pharmacol 2016;78:1317-1318.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","unstructured":"25. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007;18:149-157.","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2141.2012.09247.x","article-title":"Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature","volume":"159","author":"Guirguis","year":"2012","unstructured":"26. Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 2012;159:39-49.","journal-title":"Br J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1023\/A:1008394827806","article-title":"Groupe d'Etudes des Lymphomes de l'Adulte","volume":"11","author":"Haioun","year":"2000","unstructured":"27. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Briere J, Reyes F. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000;11:685-690.","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne MJ, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Ovlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Struessmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P. Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients. Blood 2022.","DOI":"10.1182\/blood.2021014506"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4103\/ijc.IJC_241_17","article-title":"Long-term outcome of diffuse large B-cell lymphoma: impact of biosimilar rituximab and radiation","volume":"54","author":"Ganesan","year":"2017","unstructured":"29. Ganesan P, Sagar TG, Kannan K, Radhakrishnan V, Rajaraman S, John A, Sundersingh S, Mahajan V, Ganesan TS. Long-term outcome of diffuse large B-cell lymphoma: impact of biosimilar rituximab and radiation. Indian J Cancer 2017;54:430-435.","journal-title":"Indian J Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/13696998.2019.1702990","article-title":"Real-world costs of illness of Hodgkin and the main B-cell non-Hodgkin lymphomas in France","volume":"23","author":"Mounie","year":"2020","unstructured":"30. Mounie M, Costa N, Conte C, Petiot D, Fabre D, Despas F, Lapeyre-Mestre M, Laurent G, Savy N, Molinier L. Real-world costs of illness of Hodgkin and the main B-cell non-Hodgkin lymphomas in France. J Med Econ 2020;23:235-242.","journal-title":"J Med Econ"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T11:41:17Z","timestamp":1670413277000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-27443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2022.2022.0142","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}